Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "OPEN"

929 News Found

CORONA Remedies secures EAEU-GMP certification
News | January 23, 2026

CORONA Remedies secures EAEU-GMP certification

This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model


Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
News | January 16, 2026

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign


Zydus receives final approval from USFDA for Eltrombopag Tablets
Drug Approval | January 16, 2026

Zydus receives final approval from USFDA for Eltrombopag Tablets

Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad


EMA and FDA unveil joint AI principles to transform drug revelopment
R&D | January 16, 2026

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation


Biocon completes Rs. 4,150 crore equity fundraise through QIP
News | January 15, 2026

Biocon completes Rs. 4,150 crore equity fundraise through QIP

The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited


GEA to power new biotechnology fermentation hub in Netherlands
Biotech | January 14, 2026

GEA to power new biotechnology fermentation hub in Netherlands

BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities


Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer
Clinical Trials | January 12, 2026

Pfizer’s BRAFTOVI combo shows breakthrough results in aggressive colorectal cancer

The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population